HMO Research Network CERT III

HMO 研究网络 CERT III

• 批准号: 7678532
• 负责人: Richard Platt
• 金额: $ 99.76万
• 依托单位: HARVARD PILGRIM HEALTH CARE, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7678532
• 关键词: HMO; Research; Network; CERT; III

DESCRIPTION (Provided by the Applicant): The HMO Research Network CERT has provided important insights into the use, safety and effectiveness of therapies and requests funding to continue leveraging populations from a collaboration of diverse health plans as generalizable sources of therapeutics evidence and as vehicles for disseminating and implementing therapeutics best practices. Our sub-theme will be post-marketing safety, although we will also continue to be active in promoting physician and patient behavior change, the uses of information technology, and health policy to optimize the use of therapeutics. The HMORN CERT's core will consist of 13 health plans of the HMO Research Network, with total membership of 11 million. All have public domain research units strongly linked to their plans' senior leadership and delivery systems. The HMORN CERT will use a Virtual Data Warehouse to facilitate use of enrollment, pharmacy, diagnosis and procedure data, which provides the highest level of patient privacy while facilitating complex multi-site studies. All sites are also implementing electronic medical records, allowing a greater range of studies. The CERT will focus on studies requiring detailed data and/or the ability to engage providers and plan members. It will also provide critical infrastructure support for ongoing DEcIDE (AHRQ) and FDA contracts, and collaborate with the NCI-funded HMORN Cancer Research Network and NIH-funded Clinical Translational Science Centers. New core studies will include both substantive and methodological work: 1) longitudinal study of the safety and efficacy of drug-eluting coronary artery stents; 2) testing new methods for rapid prospective drug safety assessment by using routinely collected electronic health data; 3) use and safety of antipsychotic medications in children, focusing on abnormalities of glycemic control, and 4) risk of serious infection with use of new biological agents for rheumatoid arthritis in the elderly. These will be complemented by additional activities, including targeted collaborations with other CERTs. New activities will include: 1) A Health Plan Consortium for Public Health, involving larger health plans, to perform drug/vaccine safety studies requiring populations of tens of millions; 2) Studies impacting Medicare & Medicaid populations; 3) An Institute for Clinical and Economic Review to facilitate dissemination of cost effective therapies by informing rational coverage decisions; and 4) Education and dissemination programs.

描述（由申请人提供）：HMO研究网络CERT为疗法的使用、安全性和有效性提供了重要见解，并请求提供资金，以继续利用来自不同健康计划合作的人群作为治疗证据的可推广来源和传播的工具和实施治疗最佳实践。我们的子主题将是上市后安全性，尽管我们也将继续积极促进医生和患者行为的改变，信息技术的使用和卫生政策，以优化治疗方法的使用。HMORN CERT的核心将由HMO研究网络的13个健康计划组成，成员总数为1100万。所有这些都有公共领域的研究单位，与他们的计划的高级领导和交付系统密切相关。HMORN CERT将使用虚拟数据仓库来促进招募、药房、诊断和程序数据的使用，这提供了最高水平的患者隐私，同时促进了复杂的多中心研究。所有研究中心也都在实施电子病历，以便进行更广泛的研究。CERT将重点关注需要详细数据和/或吸引提供者和计划成员的能力的研究。它还将为正在进行的DECIDE（AHRQ）和FDA合同提供关键的基础设施支持，并与NCI资助的HMORN癌症研究网络和NIH资助的临床转化科学中心合作。新的核心研究将包括实质性工作和方法学工作：1）药物洗脱冠状动脉支架安全性和有效性的纵向研究; 2）通过使用常规收集的电子健康数据测试快速前瞻性药物安全性评估的新方法; 3）儿童抗精神病药物的使用和安全性，重点关注血糖控制异常，和4）在老年类风湿性关节炎中使用新的生物制剂的严重感染的风险。这些活动将得到其他活动的补充，包括与其他应急小组开展有针对性的合作。新的活动将包括：1）公共卫生健康计划联盟，涉及更大的健康计划，以执行需要数千万人口的药物/疫苗安全性研究; 2）影响医疗保险和医疗补助人群的研究; 3）临床和经济审查研究所，通过告知合理的覆盖决策来促进成本效益疗法的传播;以及4）教育和传播计划。